- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04438382
Инфликсимаб и внутривенная иммуноглобулиновая терапия в лечении пациентов со стероидрезистентным пневмонитом
Оптимизация иммуносупрессии при стероидорефрактерном анти-PD-1/PD-L1 пневмоните
This phase II trial studies how well infliximab and intravenous immunoglobulin therapy work in treating patients with pneumonitis that does not respond to steroid treatment. Immunotherapy with monoclonal antibodies such as, infliximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Intravenous immunoglobulin therapy may improve pneumonitis. It is not yet known whether giving infliximab and intravenous immunoglobulin therapy will work better in treating patients with pneumonitis.
Обзор исследования
Статус
Условия
Подробное описание
PRIMARY OBJECTIVE:
I. To assess pneumonitis response to additional immunosuppression (infliximab or intravenous immunoglobulin therapy [IVIG]) in patients with steroid-refractory pneumonitis at 28-days.
SECONDARY OBJECTIVES:
I. To assess functional parameters of steroid-refractory pneumonitis at day 1, 14-days and 28-days after day 1 of receipt of additional immunosuppression (infliximab or IVIG).
II. To assess radiologic parameters of steroid-refractory pneumonitis at day 1, 14-days and 28-days after day 1 of receipt of additional immunosuppression (infliximab or IVIG).
III. To assess patient-reported outcomes of steroid-refractory pneumonitis at day 1, 14-days and 28-days after day 1 of receipt of additional immunosuppression (infliximab or IVIG).
IV. To assess death after additional immunosuppression. V. To assess the rate of infections in the 28-day period after additional immunosuppression.
EXPLORATORY OBJECTIVES:
I. To examine lung tissue, bronchoalveolar lavage (BAL) and serial blood samples in patients who develop steroid-refractory pneumonitis.
II. To examine associations between BAL phenotypes and pneumonitis response, functional and radiologic parameters of pneumonitis.
III. To evaluate associations between pneumonitis and autoantibodies, T-cell expansion, and baseline cytokines in the blood.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive infliximab intravenously (IV) on day 1 followed by prednisone taper IV or orally (PO) for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive an additional dose of infliximab IV on day 14 at the discretion of the treating physician.
ARM B: Patients receive intravenous immunoglobulin therapy IV over 2-5 days per institutional guidelines followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 28, 42 and 56 days.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
Контакты и местонахождение
Места учебы
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60611
- Northwestern University
-
-
Maryland
-
Baltimore, Maryland, Соединенные Штаты, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Michigan
-
Battle Creek, Michigan, Соединенные Штаты, 49017
- Bronson Battle Creek
-
Grand Rapids, Michigan, Соединенные Штаты, 49503
- Spectrum Health at Butterworth Campus
-
Grand Rapids, Michigan, Соединенные Штаты, 49503
- Mercy Health Saint Mary's
-
Kalamazoo, Michigan, Соединенные Штаты, 49007
- West Michigan Cancer Center
-
Muskegon, Michigan, Соединенные Штаты, 49444
- Mercy Health Mercy Campus
-
Niles, Michigan, Соединенные Штаты, 49120
- Lakeland Hospital Niles
-
Norton Shores, Michigan, Соединенные Штаты, 49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Соединенные Штаты, 49677
- Spectrum Health Reed City Hospital
-
Saint Joseph, Michigan, Соединенные Штаты, 49085
- Lakeland Medical Center Saint Joseph
-
Saint Joseph, Michigan, Соединенные Штаты, 49085
- Marie Yeager Cancer Center
-
Traverse City, Michigan, Соединенные Штаты, 49684
- Munson Medical Center
-
Wyoming, Michigan, Соединенные Штаты, 49519
- Metro Health Hospital
-
-
New York
-
New York, New York, Соединенные Штаты, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19111
- Fox Chase Cancer Center
-
-
Virginia
-
Richmond, Virginia, Соединенные Штаты, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Соединенные Штаты, 23298
- Virginia Commonwealth University/Massey Cancer Center
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
Patients must be English-speaking and be able to provide informed consent
-
Patient must be willing and able to undergo arterial blood gas assessment as per the treating investigator. Patient must not have contraindication for arterial blood gas assessment
-
Women must not be pregnant or breast-feeding due to the potential risk to the fetus of infliximab or IVIG. All females of childbearing potential must have a blood test or urine test within 14 days prior to randomization to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
-
Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method(s) of contraception or to abstain from sexual intercourse for a minimum of 56 days (the duration of their participation in the study)
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3
-
Patient may have received any number of lines of prior systemic therapy
-
Patient may have any solid tumor or hematologic malignancy is eligible
-
Patient must have received treatment with an anti-PD-1/PD-L1 agent either alone or in combination with another anti-cancer agent, as their most recent therapy prior to development of pneumonitis
-
Patient must have steroid-refractory pneumonitis defined as:
- Grade 2 pneumonitis that has not clinically improved by a Common Terminology Criteria for Adverse Events (CTCAE) grade in greater than 72 hours or maximum of 14 days or
- Grade 3 or higher pneumonitis that has not clinically improved by a CTCAE grade in greater than 48 hours or maximum of 14 days with high dose corticosteroids (methylprednisolone or prednisone 1-4 mg/kg/equivalent) as their most recent treatment for pneumonitis, as determined by the treating investigator
-
Patient may have received anti-PD-1/PD-L1 therapy as standard-of-care or part of a clinical trial
-
Patient must have had pathogen-negative infectious diagnostic evaluation within 14 days prior to randomization, and at a minimum these should include: blood culture, urine culture, sputum culture, and viral panel: rapid flu, respiratory syncytial virus (RSV), herpes simplex virus (HSV). Empiric antibiotics for culture negative infections are not an exclusion for study entry
-
Patient must have had a pathogen-negative bronchoscopic assessment of BAL fluid within 14 days prior to randomization. A minimum assessment for pathogens on BAL must include: gram stain, fungal panel, viral panel
-
Patient must have a negative tuberculosis assessment (TB spot test, quantiferon gold or tuberculin skin test) within 14 days prior to randomization
-
Patient must have chest computed tomography (CT) scan without contrast performed =< 14 days before randomization. Patient must not have a contraindication for CT
Exclusion Criteria:
- Patient must not have clinical evidence of cardiac dysfunction (as determined by the treating investigator) as an alternative diagnosis to steroid-refractory pneumonitis
- Patient must not be receiving anti-PD-1/-PD-L1 agent in combination with any of the following anti-cancer agents: docetaxel, cyclophosphamide, gefitinib, erlotinib, osimertinib, crizotinib, bleomycin, afatinib
- Patient must not be receiving concurrent radiation therapy to the chest
- Patient must not be deemed to have radiation pneumonitis. Patients with a history of stable radiation pneumonitis not requiring corticosteroid therapy within the last 3 months prior to randomization will be allowed on study
- Patient must not have pre-existing interstitial lung disease or pneumonitis requiring corticosteroid therapy from any other cause, as determined by the treating investigator
- Patient must not have an absolute contraindication to IVIG or infliximab, including: clinical history of severe hypersensitivity reaction, selective IgA deficiency, active hepatitis B, active tuberculosis, active human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) where a study subject has a CD4 count of =< 200 at screening, or drug interaction
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Arm A (infliximab)
Patients receive infliximab IV on day 1 followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive an additional dose of infliximab IV on day 14 at the discretion of the treating physician. |
Given IV
Другие имена:
Given IV or PO
Другие имена:
Given IV or PO
Другие имена:
|
|
Экспериментальный: Arm B (intravenous immunoglobulin therapy)
Patients receive intravenous immunoglobulin therapy IV over 2-5 days per institutional guidelines followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity. |
Given IV or PO
Другие имена:
Given IV or PO
Другие имена:
Given IV
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Pneumonitis Response Rate
Временное ограничение: At day 28
|
Pneumonitis response will be defined as an improvement in partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) of >= 20% measured by PaO2 and recording of the FiO2 received by the patient at the time of the arterial blood gas assessment, on day 28 compared with day 1. |
At day 28
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Proportion of Patients With Radiologic Response for Steroid-refractory Pneumonitis
Временное ограничение: At days 1, 14, and 28
|
Radiologic features of steroid-refractory pneumonitis will be assessed by percentage lung parenchyma involved, percentage of ground-glass opacity in lung parenchyma, and lung volume on computed tomography. The pneumonitis and lung volume will be graded "Definitely decreased", "Probably decreased", "No significant change", "Probably increased" and "Definitely increased". Response to study therapy will be defined by combining the categories "Definitely decreased" and "Probably decreased". |
At days 1, 14, and 28
|
|
Functional Parameters of Steroid-refractory Pneumonitis by Spirometry
Временное ограничение: At days 1, 14, and 28
|
Functional features of pneumonitis will be assessed by spirometry (forced vital capacity, forced expiratory volume in one second). These quantitative measures will be reported descriptively (by median, mean, and range) by timepoints and treatment arms. |
At days 1, 14, and 28
|
|
Functional Parameters of Steroid-refractory Pneumonitis by Diffusion Capacity
Временное ограничение: At days 1, 14, and 28
|
Functional features of pneumonitis will be assessed by diffusion capacity of the lung. These quantitative measures will be reported descriptively (by median, mean, and range) by timepoints and treatment arms. |
At days 1, 14, and 28
|
|
Functional Parameters of Steroid-refractory Pneumonitis by Oxygen Saturation
Временное ограничение: At days 1, 14, and 28
|
Functional features of pneumonitis will be assessed by oxygen saturation on room air at rest, collected as part of the vital signs. These quantitative measures will be reported descriptively (by median, mean, and range) by timepoints and treatment arms. |
At days 1, 14, and 28
|
|
Number of Deaths Within 28 Days
Временное ограничение: Up to 28 days
|
Death reported in the 28-day period will be tabulated by treatment arm, and classified as pneumonitis-related, immunosuppression related, disease-related or other. |
Up to 28 days
|
|
Incidence of Adverse Events
Временное ограничение: Up to 28 days
|
Will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The number and severity of treatment-related adverse events from infections in any organ system by the CTCAE reported in the 28-day period after additional immunosuppression. |
Up to 28 days
|
|
Total Score of Functional Assessment of Cancer Therapy - Lung Version 4
Временное ограничение: At days 1, 14, and 28
|
Patient-reported outcomes of steroid-refractory pneumonitis will be measured by questionnaires (Functional Assessment of Cancer Therapy - Lung version 4 [FACT-L]). FACT-L consists of 5 subscales and the total score is calculated by summing the scores of the 36 items. The score ranges between 0 and 136. The higher the score, the better the quality of life. |
At days 1, 14, and 28
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Distribution of Biomarkers in Patients Who Develop Steroid-refractory Pneumonitis
Временное ограничение: Days 1, 14 and 28 after study treatment
|
Potential blood/serum biomarkers for pneumonitis will be assessed from serially collected blood/serum in accrued patients (on Days 1, 14 and 28 after study treatment) and controls, whose blood/serum will be obtained as part of a parallel tissue-collection protocol. |
Days 1, 14 and 28 after study treatment
|
|
To Evaluate Associations Between Pneumonitis and Autoantibodies, T Cell Expansion, and Baseline Cytokines in the Blood
Временное ограничение: On days 1, 14, and 28 post-treatment
|
To evaluate associations between pneumonitis and autoantibodies, T cell expansion, and baseline cytokines in the blood. |
On days 1, 14, and 28 post-treatment
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Главный следователь: Jarushka Naidoo, ECOG-ACRIN Cancer Research Group
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Новообразования по локализации
- Новообразования
- Гематологические заболевания
- Гемики и лимфатические заболевания
- Гематологические новообразования
- Аминокислоты, пептиды и белки
- Белки
- Полициклические соединения
- Антитела, моноклональные
- Антитела
- Иммунопротеины
- Белки крови
- Сывороточные глобулины
- Глобулины
- Беременные
- Беременные
- Стероиды
- Соединения слитого кольца
- Bergyadienetriols
- Беременные
- Изотиотипы иммуноглобулина
- Иммуноглобулин г
- Преднизолон
- Метилпреднизолона ацетат
- Инфликсимаб
- Преднизолон
- Иммуноглобулины
- Метилпреднизолон
- Метилпреднизолона гемисукцинат
- Иммуноглобулины внутривенно
- гамма-глобулины
Другие идентификационные номера исследования
- EAQ172
- EAQ172 (Другой идентификатор: CTEP)
- NCI-2018-02825 (Идентификатор реестра: CTRP (Clinical Trial Reporting Program))
- UG1CA189828 (Грант/контракт NIH США)
- EAQ172 (Другой идентификатор: ECOG-ACRIN Cancer Research Group)
- EAQ172 (Другой идентификатор: DCP)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .